Chinese Cell Culture Media Leader BioEngine Celebrates 10th Anniversary Amid IPO Filing

On December 24, 2024, Shanghai Beitongji Biotechnology Co., Ltd. (BIOENFINE), a leading domestic manufacturer of cell culture media, celebrated its glorious 10th anniversary milestone. Grand celebrations were held at both BIOENFINE’s Pujiang headquarters and its Jinshan factory, where enthusiastic employees gathered to witness this significant moment together.

Professor Tan Wensong, Founder and Chairman of BIOENFINE, delivered the opening remarks: “I am delighted to join you all in celebrating BIOENFINE’s ten-year journey through trials and tribulations. Over the past decade, we have steadfastly adhered to the philosophy of ‘doing what is difficult yet right.’ By ‘right,’ we mean our commitment to creating value and significance, tackling key technologies in cell culture, and driving the development of the biopharmaceutical industry. The ‘difficult’ aspect is reflected in our unwavering perseverance in the face of challenges and hardships.” Professor Tan fondly reviewed the company’s ten-year development trajectory, noting that every step—from the arduous early days of entrepreneurship to its current steady growth—has been imbued with the wisdom and sweat of the BIOENFINE team. He particularly emphasized, “Our employees are the company’s most valuable asset. It is this team, capable of rising to challenges and overcoming obstacles in R&D, production, and management, that has shaped BIOENFINE’s present success and serves as the key to shaping our future.” Looking ahead, Professor Tan stated, “We will continue to be led by technological innovation, guided by customer needs, and grounded in quality assurance, dedicating ourselves to translating BIOENFINE’s achievements into health benefits for the public and realizing our corporate vision.”

In his address, Dr. Liu Xuping, President of BioEngine, shared the company’s original aspirations and vision: “The name ‘BioEngine’ not only reflects our pursuit of internationalization but also embodies our commitment to becoming a ‘powerful engine’ in the biopharmaceutical industry.” Dr. Liu expressed pride in the company’s achievements over the past decade and emphasized its corporate culture rooted in passion and optimism. Within just ten years, BioEngine has achieved numerous “firsts in China” and “world-first” project outcomes, developed more than 100 cell culture media products, supported over 100 clinical trial applications, and served more than 400 domestic and international partners. He stated, “People at BioEngine have always maintained their passion for work and optimism about the future; this spirit is the driving force behind BioEngine’s continuous progress.” Expressing confidence in the company’s future, he added, “We will stay true to our original mission and continue to promote BioEngine’s products and services globally, realizing our shared ideals.”

Shanghai Beitongji Biotechnology Co., Ltd., established on December 24, 2014, is a leading Chinese enterprise in the cell culture media industry. The company specializes in technical services and raw material development and manufacturing for large-scale, high-density, serum-free suspension culture of animal cells, providing biopharmaceutical companies with one-stop solutions ranging from cell culture process development and optimization, and culture medium formulation design to medium processing and manufacturing.

Leveraging nearly four decades of technical expertise and application experience in animal cell culture processes and bioreactor engineering by its founding team, BIOENFINE holds more than 60 independent intellectual property rights and has independently developed nearly 100 serum-free media products. Since its establishment, BIOENFINE has provided products and technical services to clients in the biopharmaceutical industry, including those involved in antibodies, vaccines, stem cells, and cell therapies. The company has supported over 100 clinical trial applications and delivered nearly 100 cell culture technical service projects. BIOENFINE has achieved numerous outstanding accomplishments, marking multiple “firsts in China” and “world firsts” within the industry.

BIOENFINE’s production base and its wholly-owned subsidiary, Beijin Biology, constitute a world-class culture media manufacturing facility that has fully achieved large-scale, digitalized, and internationalized operations. The production base officially commenced operations in 2021. It was constructed in compliance with Good Manufacturing Practice (GMP) requirements and has obtained multiple international quality system certifications, including ISO 13485:2016 and the Medical Device Single Audit Program (MDSAP) covering the U.S. FDA. By integrating five core systems—Product Lifecycle Management (PLM), Enterprise Resource Planning (ERP), Manufacturing Execution System (MES), Laboratory Information Management System (LIMS), and Quality Management System (QMS)—the facility implements digitalized production management to ensure stable and efficient product manufacturing. The base has established scaled-up low-temperature cone blending and jet milling processes for powder production at volumes of 1,000 liters, 10,000 liters, and 100,000 liters, with a maximum batch size of 100,000 liters. Its annual production capacity reaches 55 million liters for powdered culture media and 250,000 liters for liquid culture media, thereby ensuring a stable and reliable product supply.

BIOENFINE is committed to becoming the world’s most trusted partner in cell culture, continuously driving the development of the global biopharmaceutical industry by providing innovative solutions and reliable services.